Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
39
Journal Issue
27
Pages
2991
Date Issued
2021-09-20
Author(s)
Kelley, Robin Kate
Sangro, Bruno
Harris, William
Ikeda, Masafumi
Okusaka, Takuji
Kang, Yoon-Koo
Qin, Shukui
Tai, David W-M
Lim, Ho Yeong
Yau, Thomas
Yong, Wei-Peng
Gasbarrini, Antonio
Damian, Silvia
Bruix, Jordi
Borad, Mitesh
Bendell, Johanna
Kim, Tae-You
Standifer, Nathan
He, Philip
Makowsky, Mallory
Negro, Alejandra
Kudo, Masatoshi
Abou-Alfa, Ghassan K
Abstract
This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unresectable hepatocellular carcinoma (HCC), including a novel regimen featuring a single, priming dose of tremelimumab (ClinicalTrials.gov identifier: NCT02519348).
Subjects
METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; RESPONSE CRITERIA; THERAPY; IPILIMUMAB; SURVIVAL; TRIAL; SORAFENIB; NIVOLUMAB; BLOCKADE
SDGs
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Type
journal article